

552095

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



Rec'd PCT/P 04 OCT 2005

10/552095



(43) International Publication Date
14 October 2004 (14.10.2004)

PCT

(10) International Publication Number
WO 2004/087227 A1

(51) International Patent Classification⁷: A61L 15/22,
15/32, 24/10, 24/04, 26/00, 31/04

(21) International Application Number:
PCT/GB2004/001464

(22) International Filing Date: 2 April 2004 (02.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0307765.8 4 April 2003 (04.04.2003) GB
0317447.1 25 July 2003 (25.07.2003) GB
0318871.1 12 August 2003 (12.08.2003) GB

(71) Applicant (for all designated States except US): TISSUEMED LIMITED [GB/GB]; 5 Killingbeck Drive, Leeds LS14 6UF (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): FORTUNE, David, Harry [GB/GB]; Tissuemed Limited, 5 Killingbeck Drive, Leeds LS14 6UF (GB). KETTLEWELL, Graeme [GB/GB]; Tissuemed Limited, 5 Killingbeck Drive, Leeds LS14 6UF (GB). MANDLEY, David, John [GB/GB];

Tissuemed Limited, 5 Killingbeck Drive, Leeds LS14 6UF (GB). THOMPSON, Ian [GB/GB]; Tissuemed Limited, 5 Killingbeck Drive, Leeds LS14 6UF (GB). COOK, Diane [GB/GB]; Tissuemed Limited, 5 Killingbeck Drive, Leeds LS14 6UF (GB).


(74) Agent: JONES, Stephen, Anthony; Adamson Jones, Broadway Business Centre, 32a Stoney Street, Nottingham NG1 1LL (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: TISSUE-ADHESIVE FORMULATIONS



(57) Abstract: A tissue-adhesive formulation consists of a naturally occurring or synthetic polymerisable and/or cross-linkable material in particulate form, the polymerisable and/or cross-linkable material being in admixture with particulate material comprising tissue-reactive functional groups. The formulation may be used in the preparation of a tissue-adhesive sheet, by applying the formulation to at least one side of a core of a naturally occurring or synthetic polymeric material.

WO 2004/087227 A1



Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT,*

LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

- *of inventorship (Rule 4.17(iv)) for US only*

Published:

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Title – Tissue-adhesive formulations

Field of the Invention

5 This invention relates to materials suitable for use as tissue adhesives and sealants, and to a flexible multilamellar sheet, patch or film comprising such materials for topical application to internal and external surfaces of the body, for therapeutic purposes. The invention also relates to a process for the preparation of such products, and to methods of using such products. In
10 particular the invention relates to materials that are formulated as loose or compacted powders and to a self-adhesive, biocompatible and hydratable polymeric sheet with such materials applied to a suitable support, which may be used for therapeutic purposes such as wound healing, joining, sealing and reinforcing weakened tissue, and for drug delivery, and to a process for
15 preparing, and methods of using, such a sheet.

Background of the Invention

20 There is considerable interest in the use, for a number of surgical or other therapeutic applications, of materials that adhere to biological tissues eg as an alternative to the use of mechanical fasteners such as sutures, staples etc. Formulations of such materials that have hitherto been proposed include viscous solutions or gels that are either manufactured in that form or are prepared immediately prior to use by mixing of the ingredients. Such
25 formulations are then applied to the tissue surface using a suitable applicator device such as a syringe.

Formulations of the type described above suffer from a number of disadvantages. If the formulation is of low viscosity, it may spread from the
30 area of application and hence be difficult to apply precisely to the desired area of tissue. If the formulation is more viscous, on the other hand, it may be difficult to dispense. In either case, the formulation, being prepared in

hydrated form, may have a limited lifetime and may be subject to premature curing. It may therefore be necessary for the whole of the formulation to be used at once or discarded. Also, the preparation of formulations immediately prior to use by mixing of ingredients is obviously laborious and time-consuming. In addition to these drawbacks, the degree of adhesion between tissue surfaces that is provided by such formulations may be less than would be desired.

Formulations of tissue adhesive materials have also been applied to a suitable support for application to the tissue surface. The use of therapeutic materials in the form of a sheet, patch or film, for topical administration to either internal or external organs of the body, is well documented for a wide range of medical applications. A disadvantage of products proposed hitherto, however, is that the degree of adhesion to the underlying tissue, particularly in the longer term, may be inadequate. While the initial adhesion may be satisfactory, the sheet may subsequently become detached from the tissue, often after only a few seconds or minutes, eg as a result of hydration of the sheet following its application. In addition, the flexibility of the product may be insufficient for it to conform readily to the surface to which it is applied, which may also have an adverse effect on its adhesion.

As a result of the inadequate adhesion of these products, it may be necessary to provide further reinforcement, eg through mechanical attachment using sutures, staples or the like. Alternatively, energy (eg light or heat energy) may be applied in order to initiate chemical bonding of the adhesive formulation to the underlying tissue, and hence bonding of the tissue surfaces to each other. Clearly, such approaches introduce further drawbacks. The use of mechanical fastenings such as sutures or staples is often the very thing that the use of such products is intended to replace or avoid. In many instances, the use of such fastenings is either not wholly effective (eg on the lung) or undesirable, as their introduction gives rise to further areas of tissue weakness. The use of external energy requires the provision and operation of

a source of such energy. Such energy sources may be expensive and difficult to operate, particularly in the confines of an operating theatre or similar environment. Also, the use of external energy for attachment can be both time-consuming and (in some cases) requires significant careful judgement on the part of the surgeon, to evaluate when sufficient energy has been delivered to effect attachment without damaging the underlying tissue.

There have now been devised improved formulations of tissue-adhesive materials and sheets or the like of the general type described above that overcome or substantially mitigate the above-mentioned and/or other disadvantages of the prior art.

Brief Summary of the Invention

According to a first aspect of the invention, there is provided a tissue-adhesive formulation comprising a naturally occurring or synthetic polymerisable and/or cross-linkable material in particulate form, the polymerisable and/or cross-linkable material being in admixture with particulate material comprising tissue-reactive functional groups.

20

The formulation according to the invention is advantageous primarily in that it can be easily applied to a tissue surface using a simple applicator or delivery device. As it is applied in solid form, the particulate formulation adheres to the tissue surface and does not spread unduly. The formulation exhibits good initial adhesion to the tissue surface, this being believed to be due to van der Waals forces and/or hydrogen bonding between the formulation and the tissue surface. On contact with the tissue surface the formulation becomes hydrated, thereby causing reaction between the tissue-reactive functional groups and the underlying tissue surface. Such reactions between the tissue-reactive functional groups and the underlying tissue results in high adhesion between the formulation and the tissue surface, and hence between tissues that are joined using the adhesive formulation. Reaction may also take place

25

30

between the tissue-reactive functional groups and the other components of the formulation to form a strong, flexible and tissue-adherent gel. This formulation thus absorbs physiological fluids (as a consequence of application onto exuding tissue surfaces), and any additional solutions used to hydrate
5 the formulation following application (such fluids can be commonly used solutions used in surgical irrigation), becoming gelatinous and adherent to the tissue surfaces, and thereby providing an adhesive sealant, haemostatic and pneumostatic function.

10 In addition, because the formulation is made up in solid form that is, until hydrated by contact with the tissue surface (and subsequent hydration), essentially inactive, the formulation is not prone to premature reaction and as a result its shelf-life may be considerable, eg more than six months when stored at room temperature and stored appropriately. This further enables the
15 formulation to be packaged in relatively large quantities that can be dispensed and used over a considerable time period, without the risk of substantial wastage.

According to a second aspect of the present invention, there is provided a
20 sheet having a multilayer structure, said structure comprising a core of a naturally occurring or synthetic polymeric material, the core being coated on at least one side thereof with a tissue-adhesive formulation comprising a naturally occurring or synthetic polymerisable and/or cross-linkable material in particulate form, the polymerisable and/or cross-linkable material being in
25 admixture with particulate material comprising tissue-reactive functional groups.

In preferred embodiments of the invention, the tissue-adhesive formulation is applied to the core by mechanically compressing a blend of material
30 containing tissue-reactive functional groups (hereinafter referred to as "tissue-reactive material") and the polymerisable and/or cross-linkable component, both in particulate form, onto one or both sides of the core.

The sheet according to the invention is advantageous primarily in that it bonds effectively to tissue, enabling it to be used in a variety of medical applications. The invention enables coating of the tissue-reactive materials onto (and into)
5 a three-dimensional structural support, whilst maintaining the pliability and physical properties of the support. Furthermore, the adhesive performance of the tissue-reactive materials is not compromised when delivered to the target tissue in this form. Where, as in preferred embodiments, the support is perforated, the perforations provide a means of anchoring the tissue-reactive
10 materials in the support. This reduces or eliminates cracking and crumbling of the tissue-reactive material as it is applied to the support (core), which would result in sub-optimal coverage of the target tissue, and thereby compromise the adhesive/sealant effects of the sheet.

15 The sheet exhibits good initial adhesion to the tissue to which it is applied (and may thus be described as "self-adhesive"), and furthermore remains well-adhered to the tissue over a longer timescale. Without wishing to be bound by any theory, it is believed that the initial adhesion of the sheet to the tissue is attributable to electronic bonding of the sheet to the tissue, and this is
20 supplemented or replaced by chemical bonding between the tissue-reactive functional groups of the formulation and the tissue, in particular between amine and/or thiol groups on the tissue surface and the tissue-reactive groups of the sheet. Where the structural inner core of the device is perforated, and is coated on both sides with the tissue-adhesive formulation, the perforations
25 facilitate hydration and cross-linking of the formulation on both sides of the core such that the core becomes enclosed within a three-dimensional matrix of cross-linked material.

30 The use of the sheet reduces or eliminates the need for additional means of mechanical attachment to the tissue (eg sutures or staples), or the need to provide external energy in the form of heat or light to bring about adherence of the sheet to the underlying tissue. Another advantage of the sheet according

to the invention is that it is applied to the tissue as a preformed article, rather than being prepared by mixing of materials immediately prior to use.

5 By the term "sheet" is meant a three-dimensional article with a thickness that is considerably less than its other dimensions. Such an article may alternatively be described as a patch or a film.

10 According to another aspect of the invention, there is provided a method for the manufacture of a sheet according to the second aspect of the invention, which method comprises forming a core comprising naturally occurring or synthetic polymeric material, and coating at least one side of said core with a tissue-adhesive formulation comprising a blend of a naturally occurring or synthetic polymerisable and/or cross-linkable material in particulate form and particulate material comprising tissue-reactive functional groups.

15

In a third aspect, the invention also provides a method of joining a tissue surface to another tissue, or of sealing a tissue surface, which method comprises applying to the tissue surface a formulation according to the first aspect of the invention or a sheet according to the second aspect of the invention.

20

Brief Description of the Drawings

25 Figure 1 is a schematic representation of the reaction between a tissue-reactive functional group (in the illustrated case an N-hydroxysuccinimide ester) and an amine-containing molecule such as a tissue protein.

Figure 2 shows the introduction of carboxyl group-bearing side chains into a poly(vinyl alcohol – vinyl acetate) copolymer.

30

Figure 3 represents the formation of a poly(N-vinyl-2-pyrrolidone-co-acrylic acid) copolymer.

Figure 4 shows the mechanism of free radical initiation of a polymerisation reaction.

5 Figure 5 illustrates the synthesis of a tissue reactive material.

Figure 6 is a schematic sectional view of a sheet according to the invention.

Detailed Description of the Invention

10

Composition of the formulation

The formulation according to the first aspect of the invention comprises a naturally occurring or synthetic polymerisable and/or cross-linkable material in
15 particulate form, and a particulate material comprising tissue-reactive functional groups.

These two components may be blended in suitable proportions, which may depend on the particular materials used, as well as the desired properties of
20 the resulting blend. Typically, the ratio by weight of polymerisable and/or cross-linkable material to tissue-reactive material will be between 0.1:1 and 10:1, more preferably between 0.2:1 and 1:1.

The particles that make up the formulation have a wide range of particle sizes.
25 The median particle size may, for instance, lie in the range 5µm to 500µm, more preferably 5µm to 100µm.

Nature of the polymerisable and/or cross-linkable component

30 One component of the formulation is a polymerisable and/or cross-linkable material.

By "polymerisable" is meant that the material may be present in the formulation as a prepolymer or macromer in monomeric or only partially polymerised form, such that upon hydration of the formulation the material undergoes (further) polymerisation.

5

More commonly, however, the material will be "cross-linkable", rather than "polymerisable". By this is meant that the material will be capable of forming covalent bonds between molecules. Such inter-molecular cross-linking may also be accompanied by intra-molecular cross-linking, ie formation of covalent bonds between functional groups in the same molecule.

10

The cross-linkable material will generally be polymeric or macromolecular in form, the effect of the cross-linking being to form covalent bonds between such molecules, and so to establish a three-dimensional network or matrix.

15

The cross-linkable material is preferably selected from polysaccharides, polylactates, polyols and proteins, and derivatives thereof.

20

The cross-linkable material may be in a partially crosslinked form in which individual molecules of the cross-linkable material are linked together through intermolecular covalent bonds. Such crosslinking can be effected by standard techniques known in the art, for example by heat treatment and/or crosslinking agents. Depending on the nature of the cross-linkable material and/or the conditions employed to effect crosslinking, the degree of crosslinking between individual molecules can vary considerably.

25

The degree of pre-crosslinking in the cross-linkable material, however, should not be such that it substantially prevents the subsequent reaction of the tissue-reactive functional groups with the cross-linkable material.

30

Proteins are preferred materials for the cross-linkable material because they are rich in functional groups that are reactive to tissue-reactive functional

groups. Hence, the tissue-reactive functional groups will react not only with the tissue surface to which the formulation is applied, but also with the cross-linkable material.

- 5 A particularly preferred protein for use in the invention is albumin, particularly mammalian albumin such as porcine, bovine or human albumin.

Preferred synthetic polymers that may be, or may be present in, the polymerisable and/or cross-linkable material include multifunctionally activated
10 synthetic polymers, ie synthetic polymers that have, or have been chemically modified to have, a plurality of functional groups that are capable of reacting with each other or with other functional groups present in the formulation to form covalent bonds. Preferred multifunctionally activated synthetic polymers include chemically modified polyalkylene glycols, in particular polyalkylene
15 glycols that have been modified to contain multiple primary amino or thiol groups.

Suitable modified polyalkylene glycols include both linear and branched (eg so-called "3-arm" and "4-arm") compounds. Examples of suitable multi-amino
20 polymers are those sold under the trade name JEFFAMINE. These are based on backbones of polyethylene glycol and/or polypropylene glycol units with terminal amine groups.

Other suitable synthetic materials may include, or may be based on,
25 poly(vinylamine), poly(ethyleneimine), poly(allylamine), poly(ethylene glycol-co-aspartic acid, poly(lysine-co-lactide, poly(cysteine-co-lactide) or poly(2-aminoethylmethacrylate).

In general, suitable cross-linkable materials will be materials that are solid at
30 ambient temperatures, and this may preclude the use of very low molecular weight materials.

Methods by which similar and analogous chemically modified polymers can be prepared will be readily apparent to those skilled in the art.

Nature of the tissue-reactive material

5

The tissue-reactive material is preferably polymeric in nature. Most preferably, the polymer is a synthetic polymer.

10 By "tissue-reactive functional groups" is meant functional groups capable of reacting with other functional groups present in the tissue surface so as to form covalent bonds between the formulation and the tissue. Tissues generally consist partly of proteins, which commonly contain thiol and primary amine moieties. Many functional groups such as imido ester, p-nitrophenyl carbonate, N-hydroxysuccinimide (NHS) ester, epoxide, isocyanate, acrylate,
15 vinyl sulfone, orthopyridyl-disulfide, maleimide, aldehyde, iodoacetamide, and others, may react with thiols or primary amines, and therefore constitute "tissue-reactive functional groups". As used herein, the term NHS or NHS ester is intended to encompass not only N-hydroxysuccinimide itself, but also derivatives thereof in which the succinimidyl ring is substituted. An example
20 of such a derivative is N-hydroxysulfosuccinimidyl and salts thereof, particularly the sodium salt, which may increase the solubility of the tissue-reactive material.

25 Figure 1 illustrates the mechanism by which an NHS-functionalised polymer reacts with an amine-containing material such as a tissue protein represented by $R-NH_2$. The reaction is a nucleophilic displacement leading to the formation of an amide bond between the polymer and the tissue protein.

30 Tissue-reactive functional groups that may be of utility in the present invention are any functional groups capable of reaction (under the conditions prevalent when the formulation is applied to tissue, ie in an aqueous environment and

without the application of significant amounts of heat or other external energy) with functional groups present at the surface of the tissue. The latter class of functional group includes thiol and amine groups, and tissue-reactive functional groups therefore include groups reactive to thiol and/or amine

5 groups. Examples are:

imido ester;

p-nitrophenyl carbonate;

N-hydroxysuccinimide (NHS) ester;

epoxide;

10 isocyanate;

acrylate;

vinyl sulfone;

orthopyridyl-disulfide;

maleimide;

15 aldehyde; and

iodoacetamide.

N-hydroxysuccinimide (NHS) ester is a particularly preferred tissue-reactive functional group.

20

In general, the tissue-reactive material may be formed by derivatisation of a suitable polymer precursor. Classes of polymer which lend themselves to such derivatisation include those that contain carboxylic acid or alcohol functional groups, or related structures. Polymers that may be used include
25 polymers that are commercially available or polymers that are prepared specifically for this purpose. Naturally-occurring materials such as sucrose or a derivatised cellulose may also be used.

30

Commercially available polymers that may be used include polyvinylalcohol (PVA). In the case of PVA, the functional groups may be introduced by first adding a chain extending or linking group, for example an acid functionality that can be further reacted with N-hydroxy succinimide. Figure 2 shows the

addition of a chain-extending group to a copolymer of vinyl acetate and vinyl alcohol, the chain-extending group terminating in a carboxylic acid group that may be converted to the corresponding NHS-ester. The copolymer starting material (in which molar fraction x of vinyl alcohol groups may be 0.85-0.995) is reacted with a cyclic anhydride (in the example illustrated, succinic anhydride) in the presence of a base such as pyridine. Between 5% and 40% of the alcohol groups are derivatised to form the carboxylic acid-bearing side chains (ie $a+b=x$, with a being between $0.05x$ and $0.40x$), which may then be converted to the NHS-ester by conventional methods that are known *per se*.

Where the polymer support is synthesized for the purpose of subsequent derivatization, a wide variety of monomers may be used. Examples include *N*-vinyl-2-pyrrolidone, acrylic acid, vinyl acetate, vinyl acetic acid, mono-2-(methacryloyloxy)ethyl succinate, methacrylic acid, 2-hydroxyethyl methacrylate, 2-hydroxypropyl methacrylate, (polyethylene glycol) methacrylate or other monomers containing acid or alcohol functionality. Such monomers may be polymerised via various standard polymerisation techniques, including free radical techniques using an initiator such as benzoyl peroxide, 2,2'-azobisisobutyronitrile (AIBN), lauroyl peroxide, peracetic acid etc. One preferred example of such a polymer is poly(*N*-vinyl-2-pyrrolidone-co-acrylic acid) polymerised using AIBN as initiator. The polymerization of this material is illustrated in Figure 3, in which the molar ratio of acrylic acid-derived units may be between 0 and 1.0, preferably less than 0.60, and more preferably less than 0.40, eg between 0.025 and 0.25. The copolymer may be further reacted with *N*-hydroxysuccinimide to form the tissue-reactive material.

Preferably, all or substantially all of the available sites in the precursor to the tissue-reactive material will be derivatised (ie the tissue-reactive functional groups will be introduced into all or substantially all of the available sites in the precursor to the tissue-reactive material). The degree of binding between the tissue-reactive functional groups and the tissue to which the formulation is

applied will then be a function of the amount of tissue-reactive material in the formulation.

5 Where, as is preferred, the tissue-reactive functional groups are NHS-esters, at least one of the monomers used in the preparation of the tissue-reactive material must contain a carboxylic acid group or a group capable of being reacted with another material to form an acid functionality.

10 In the preferred case in which the tissue-reactive material is a derivative of poly(N-vinyl-2-pyrrolidone-co-acrylic acid) copolymer (PVP-co-PAA), the molar ratio of acrylic acid-derived units is preferably between 0.05 and 0.50, and hence that of the vinyl pyrrolidone-derived units is between 0.50 and 0.95. The derivative is referred to as activated PVP-co-PAA.

15 The acrylic acid groups are preferably derivatised to form tissue-reactive (activated) groups, most preferably with NHS groups. A copolymer of vinyl pyrrolidone and acrylic acid, in which the carboxyl groups of the acrylic acid-derived units carry NHS groups, is referred to herein as NHS-activated PVP-co-PAA.

20 As noted above, the activity of the tissue-reactive material (ie the degree to which the tissue-reactive functional groups of that material bind to the tissue) may be controlled by varying the proportion of that material in the formulation. The concentration of the tissue-reactive material in the formulation may be
25 varied quite widely, eg from 10% w/w or less up to 50% w/w or more.

The formulation may contain one type of tissue-reactive material, or more than one type of tissue-reactive material.

30 In addition to forming covalent bonds with the surface to which it is applied, the tissue-reactive material may also have bioadhesive properties. By this is meant that the material should exhibit good initial adhesion to biological tissue

to which it is applied. Polymers with such properties typically contain chemical groups with a high ionic density, eg carboxyl, amide, lactam, hydroxyl, ether and ester groups, and the salts thereof, which interact cooperatively with tissue, through the formation of ionic and hydrogen bonds, dipole - dipole interactions and Van der Waals forces. Effective polymers are generally of high molecular weight since the degree of bioadhesion may be proportional to the number of these groups available. Typically, the molecular weight of a bioadhesive polymer will be in excess of about 50,000. The polymers are also generally linear, becoming physically entangled and having an amorphous distribution in solution.

For example, the tissue-reactive polymer may be derivatised PVP or a derivatised copolymer of vinyl pyrrolidone with another monomer (eg acrylic acid). In such a case, the pendant pyrrolidone groups will provide immediate contact adhesion (believed to be due to hydrogen and/or van der Waals bonding, as described above), while the tissue-reactive groups then form covalent bonds with functional groups within the tissue and within the matrix (cross-linking).

Thus, according to another aspect of the invention there is provided a biocompatible and hydratable composition suitable for topical application to internal or external surfaces of the body, which matrix comprises a polymer containing tissue-reactive functional groups and a polymer containing groups that are not tissue-reactive functional groups but which are capable of forming hydrogen bonds with groups at the surface of a tissue to which the matrix is applied.

The tissue-reactive functional groups may be as described above. The groups that are capable of forming hydrogen bonds ("hydrogen-bonding groups") are preferably electron-rich groups, eg selected from amide, lactam, carbonyl, carboxyl, hydroxyl and ether groups.

In a particular embodiment, the tissue-reactive groups and the hydrogen-bonding groups are present in the same polymer. The invention thus provides a biocompatible and hydratable composition suitable for topical application to internal or external surfaces of the body, which composition comprises a polymer containing tissue-reactive functional groups and groups that are not tissue-reactive functional groups but which are capable of forming hydrogen bonds with groups at the surface of a tissue to which the matrix is applied.

The tissue-reactive groups are preferably tissue-reactive ester groups, especially NHS-ester groups, and the hydrogen-bonding groups are preferably amide or lactam groups. The polymer is thus preferably activated PVP-co-PAA, especially NHS-activated PVP-co-PAA.

Alternatively, the tissue-reactive groups and the hydrogen-bonding groups may be present in different polymers. In addition to the tissue-reactive material, therefore, the formulation according to the invention may further comprise a polymer containing hydrogen-bonding groups. Examples of suitable polymers are poly(vinyllic acids) and copolymers thereof. However, a preferred group of bioadhesive polymers are polymers consisting of a hydrocarbon backbone with pendant amide or lactam groups, or recurring structural units containing such groups. Preferably, the recurring unit is, or contains, a 1-ethylenepyrrolidin-2-one (vinylpyrrolidone) group. Homopolymers containing recurring N-vinyl-2-pyrrolidone groups are particularly preferred, ie poly(vinylpyrrolidone) (PVP).

PVP has been found to be suitable for use in the present invention for numerous reasons. First, it is readily available in a variety of grades and molecular weights, and has a long history of use in medical applications. PVP has a linear structure, is stable over wide ranges of pH and temperature, and is readily and rapidly soluble in water and other solvents.

Without wishing to be bound by any particular theory, it is believed that the good bioadhesive properties of PVP are attributable to the fact that the carbonyl group and nitrogen atom of the pendant pyrrolidone moiety are electron-rich. The material is therefore capable of effectively immediate
5 adhesion to the tissue to which it is applied through hydrogen bonds formed with functional groups at the surface of the tissue and/or through van der Waals forces.

10 The bioadhesive polymer may alternatively be a copolymer, eg a copolymer of amide- or lactam-containing units as described above and a vinylic acid. One particular form of copolymer that may be suitable is thus poly(vinylpyrrolidone-co-acrylic acid) (referred to herein as PVP-co-PAA).

15 Other groups of polymers that may exhibit suitable bioadhesive properties include cellulose derivatives, particularly cellulose ethers and derivatives and salts thereof. Examples include carboxymethyl cellulose (CMC) and salts thereof, hydroxypropylmethyl cellulose and hydroxyethylmethyl cellulose. Sodium carboxymethyl cellulose is one example of such a polymer.

20 Combinations of polymers of the kinds described above may be employed. One preferred example is a combination of a polymer of amide- or lactam-containing units as described above and a cellulose derivative as described above. A particular combination is PVP and a salt, eg the sodium salt, of CMC.

25

Sufficiency of the degree of initial adhesion of a sheet to the tissue, by the bioadhesive polymer(s), can be quantitatively determined *in vitro*, for example by performing an adhesion strength test. This test is performed by allowing the sheet to adhere to a suitable substrate (secured in a fixed position), while
30 the sheet itself is physically attached at a separate point to the load of a tensile testing apparatus, positioned so that, prior to the test, the sheet is not under load. The load cell is moveable along an axis substantially

perpendicular to that along which the substrate is positioned. The test involves movement of the load cell away from the substrate, at a constant predetermined rate, until the sheet detaches from the substrate. The output of the test is a quantitative measure of the energy of adhesion for that sheet – ie the cumulative amount of energy required to break the interaction between the sheet and the substrate to which it is adhered. A suitable cumulative energy of adhesion for the sheet according to the invention would be not less than 0.1mJ, more preferably not less than 0.25mJ, and most preferably not less than 0.5mJ.

Manufacture of the components of the formulation

The particulate tissue-reactive material and the particulate polymerisable and/or cross-linkable component may be prepared by any suitable means.

Particularly where the latter component is proteinaceous, the particles are preferably prepared by freeze- or heat-drying of an aqueous solution or suspension.

To enhance the reaction between the tissue-reactive material (which is typically an electrophile-rich material) and the polymerisable and/or cross-linkable material (which is typically nucleophilic), it may be necessary or desirable to buffer the latter component to alkaline levels to promote proton extraction.

It should be apparent to those skilled in the art that the reaction between electrophilic and nucleophilic compounds may be controlled by adjusting the pH of the reaction. As the pH is adjusted above 7, the crosslinking reaction becomes more favourable.

In preferred embodiments of the present invention, polymerisable and/or cross-linkable nucleophile-rich materials are processed by alkaline buffering and subsequent lyophilisation. These materials are subsequently mixed with

tissue-reactive materials in a dehydrated form. Upon hydration (ie during application onto tissue surfaces) the alkaline buffering of the formulation ensures effective reaction between the crosslinkable material and the associated tissue-reactive material.

5

By using such a method, the need for the components of the formulation to be buffered separately immediately prior to use is eliminated. The novel method described herein eliminates the requirement to "prime" the target site or to prepare a range of buffered solutions in order to effect a cross-linking

10

The degree of buffering required is dependent on the cross-linkable material being utilised and the conditions required to abstract a proton therefrom. For example, it has been found that for human albumin the optimal pH required to ensure effective crosslinking is in the range pH 9-11. For synthetic polymeric compounds such as polyvinylamine, on the other hand, equally effective reactivity is demonstrated at pH 7-8.

15

Thus, in preferred embodiments of the invention, the polymerisable and/or cross-linkable material is buffered to a pH greater than 7.

20

The formulation may be prepared simply by admixing the components in particulate form, and where desired compacting the formulation to form tablets, plugs or the like. The degree of compaction should be such that the tablets etc retain their integrity until applied to tissue, but not so great as to inhibit hydration (and hence adhesion) after application.

25

Physical forms of the formulation

The formulation according to the invention may have the form of a loose powder, in which particles of the tissue-reactive material are admixed with particles of the polymerisable and/or cross-linkable component.

30

Alternatively, the formulation may take the form of a compacted body formed by compaction of the particles. Tissue-reactive materials based on poly (N-vinyl-2-pyrrolidone) or copolymers of N-vinyl-2-pyrrolidone with other
5 monomers (eg vinylic monomers) are particularly preferred in such applications, as poly (N-vinyl pyrrolidone) has suitable flow properties for blending with other components of the formulation, and exhibits excellent performance in dry granulation tableting processes as it undergoes plastic deformation on compression, and has low hygroscopicity.

10 In a further alternative, the formulation may be applied to a core to form a sheet according to the second aspect of the invention.

15 Sheets in accordance with the invention may be planar, or may be folded, fluted, coiled or otherwise formed into more complex shapes.

The formulation may further comprise additional components such as structural polymers, surfactants, plasticizers and excipients commonly used in tablet manufacture. Such further components may be present as discrete
20 particles, or may be components of the particles of tissue-reactive material and/or polymerisable and/or cross-linkable component.

Nature of the core

25 The principal functions of the core are to provide the sheet with structural integrity and to provide a flexible substrate onto which the tissue-reactive formulation, in powder form, can be applied.

30 The core can be prepared using any suitable polymeric material or combination of materials. The core may be biodegradable or non-biodegradable, and should be biocompatible, ie should be capable of

application to tissues either within or external to the body without causing any immunological or other adverse reaction.

Examples of polymeric materials that may be used for the core are:

5

Polymers or co-polymers based on α -hydroxy acids, such as polylactide, polyglycolide; and also polycaprolactone and other polylactones such as butyro- and valerolactone.

10 Other examples may include:

alginates (ie polymers based on alginic acid, the polysaccharide obtained from seaweeds);

polyhydroxyalkanoates;

15 polyamides;

polyethylene;

propylene glycol;

water-soluble glass fibre;

starch;

20 cellulose;

collagen;

pericardium;

albumin;

polyester;

25 polyurethane;

polyetheretherketone (PEEK);

polypropylene; and

polytetrafluoroethylene.

30 The core may be prepared by casting, spinning or foaming of a solution of the polymeric material, or by moulding, weaving of filamentous material, or slicing

from a block of material. Appropriate techniques for the preparation of the core by such methods will be familiar to those skilled in the art.

5 In preferred embodiments, the core is formed with a regular array of apertures, for example in a square or hexagonal array. The apertures may be formed during manufacture of the core or may be introduced after the core is formed, for example by piercing.

10 Preferably, the apertures are between 50µm and 2mm in diameter and adjacent apertures are formed at a centre-to-centre separation of between 100µm and 5mm. Preferably, the apertures account for between 5% and 80% of the overall surface area of the core.

The core may have a thickness of from 0.005 to 5mm.

15

Application of the formulation to the core

The formulation may be applied to just one side of the core. More preferably, however, the formulation is applied to both sides of the core.

20

Where the core is apertured, application of the formulation to one or both sides of the core causes the apertures to be filled with the formulation. In use, where the formulation is applied to both sides of an apertured core, the formulation that is present in the perforations effectively binds together the
25 activated coatings on each side of the core, encapsulating the core between the two layers of activated coating.

The preferred method for applying the formulation to the core involves mechanically compressing (eg using a hydraulic press) a blend of the tissue-
30 reactive material and the polymerisable and/or cross-linkable component, both in particulate form, onto one or both sides of the core.

The blend may be prepared by admixing particles of the tissue-reactive material with particles of the polymerisable and/or cross-linkable component.

5 The coating formulation may include filler materials that may typically account for up to 50% by weight of the coating formulation. Examples of such materials include cellulose derivatives (eg carboxymethyl cellulose, hydroxypropyl methylcellulose, etc), polyethylene glycol, polyvinylpyrrolidone and other commonly used pharmaceutical excipients.

10 The thickness of the coating applied to one or both sides of the core will typically be between 50µm and 500µm, more commonly from about 70µm to about 200µm.

15 Optionally, a surface of the sheet that, in use, is not intended to adhere to tissue may be coated with a non-adhesive material. Most preferably, such a material is a synthetic polymer. Examples of suitable polymers include polyethylene glycols, polylactide and poly(lactide-co-glycolide). A sheet with such a non-adhesive coating will adhere only to the target tissue (to which the underside of the sheet is applied) and not to surrounding tissues (eg the
20 pleural or peritoneal wall). The non-adhesive coating may include a visibly-absorbing chromophore to enable identification of the non-tissue contacting surface of the sheet. An example of a suitable chromophore is methylthioninium chloride.

25 The non-adhesive coating is preferably also formed with apertures. In such a case, the apertures may be formed in a similar array to the apertures in the core, with similar separations between apertures. The apertures in the non-adhesive coating are, however, preferably somewhat smaller than those in the core, eg with a diameter of between 50µm and 1mm.

30

Physical form of the sheet

The sheet may typically have an overall thickness of from 0.05 to 10 mm, typically 0.05 to 2mm, and more commonly 0.05 to 0.5 mm, eg about 200µm or 300µm or 400µm.

- 5 The sheet may be produced with, or subsequently cut to, dimensions of from a few square millimetres up to several tens of square centimetres.

Therapeutic applications of the formulation and sheet

- 10 The formulation and sheet according to the invention are suitable for application to both internal and external surfaces of the body, ie they may be applied topically to the exterior of the body (eg to the skin) or to internal surfaces such as surfaces of internal organs exposed during surgical procedures, including conventional and minimally invasive surgery.

15

The formulation and sheet according to the invention are particularly suitable for surgical applications in the following areas:

Thoracic / cardiovascular

- 20 General surgery

ENT

Urology

Oral / maxillofacial

Orthopaedic

- 25 Neurological

Gastroenterology

Ophthalmology

Gynaecology / obstetrics

- 30 Possible uses are described in more detail below.

Wound healing

The degradable nature of the formulation and sheet mean that they may support and promote wound healing during both internal and topical procedures. Once the formulation and/or sheet begin to degrade, fibroblasts will move in and begin to deposit components of the extracellular matrix. The formulation and sheet can therefore be used as an internal or external dressing. In addition, factors such as growth factors and cAMP that are known to promote the proliferation of skin cells may be added to the formulation to assist in the healing process. The sheet may be designed to control the transmission of moisture and infectious agents, and thus be useful particularly in the treatment of burns.

Skin closure

The formulation and sheet may be applied topically to promote wound closure (as an alternative to sutures). This may have beneficial effects in that it may reduce scarring, and the formulation and sheet may thus be useful for cosmetic purposes during minor surgery (eg in Accident and Emergency Departments). The self-adhesive properties of the sheet make it easy to apply quickly.

Hernia repair

The sheet may be used to provide reinforcement in hernia repair procedures. The self-adhesive attachment overcomes the potential issues faced by conventional surgical reinforcing mesh products, which require suturing or stapling in an already weakened area. The sheet for such a procedure may be engineered to have short or long term durability, depending on the degree of tissue repair required. The sheet may also be able to withstand the application of staples.

Anastomosis

The formulation and self-adhesive sheet provide a means for rapid sealing of, and prevention of leaks in, joined tubular structures such as blood vessels,

and vascular and bladder grafts, and the GI tract. The ability of the sheet to support tissue repair may be of particular value if used in nerve repair.

Sealing large areas of tissue

- 5 The good sealing and handling properties of the formulation and sheet, combined with their self-adhesive properties and ability to cover a large surface area, mean that they may be of particular use in sealing resected tissue surfaces – in particular those where diffuse bleeding is an issue (eg the liver). The sheet also provides an ideal support matrix for tissue repair at
10 such sites. This could also be applicable to limiting leakage of cerebro-spinal fluid following neurological surgery.

Sealing air leaks

- In addition to the patch properties described above, the high tensile strength
15 and good inherent elasticity of the formulation and sheet (after hydration and reaction of the tissue-reactive functional groups), make them particularly suitable for sealing air leaks in the lung, particularly following lung resection. Again, after effecting a seal, the sheet provides an ideal support matrix for tissue repair at such sites.

20

Haemostasis

The formulation and sheet may be applied to a bleeding area, acting as a physical barrier. The tissue-reactive material in the formulation and sheet may immobilise proteins and thereby promote haemostasis.

25

Therapeutic agent administration

- Drugs and other therapeutic agents (including biologically active agents such as growth factors, and even cells and cellular components) may be added to solution(s) used to form the components of the formulation and sheet, or
30 covalently linked to components prior to their use in the manufacture of the formulation and sheet. Once the formulation or sheet is in place, following application to the desired site, the drug will be slowly released, either by

diffusion or by engineering the formulation or sheet so that as it degrades over time the drug is released. The rate of release can be controlled by appropriate design of the formulation and sheet. The formulation and sheet may thus provide a means for delivering a known amount of drug either systemically or to a precise locus. The drug may be directly bound to a component of the formulation, or simply dispersed in the formulation.

Prevention of Post-Surgical Adhesions

Post-surgical adhesion, the formation of undesired connective tissue between adjacent tissues, is a serious problem which can give rise to major post-surgical complications. It is a particular problem in bowel surgery where it can cause, for instance, twisting of the bowel, which may then necessitate further surgical intervention. The application of sheet material having self-adhesive properties in accordance with the invention to tissues exposed in a surgical procedure can be effective in preventing post-surgical adhesions between that tissue and neighbouring tissues.

Minimally Invasive Procedures

The use of minimally invasive techniques for taking tissue samples by biopsy, inserting devices, delivery of therapeutic agents and performing surgical procedures is rapidly developing as an alternative choice to traditional "open" surgery. Minimally invasive procedures typically result in less pain, scarring, quicker recovery time and fewer post-operative complications for patients, as well as a reduction in health care costs. Procedures are undertaken using specially designed instruments which are inserted through small keyhole-sized surgical incisions. The formulation and sheet may be introduced into the body via existing and specially designed minimally invasive surgery instruments and trocar systems, and the sheet may be shaped or prepared to an appropriate size and configuration. The format of the formulation also may be modified to enable delivery of powders, tablets, pellets, tapes/strips/pellets and other 3-D matrices. The use of a self adhesive formulation will

significantly reduce the technical difficulties associated with manipulating, closing and repairing tissues where access is restricted. In addition the sheet properties make them particularly suitable for sealing leaks of air, blood or fluid or for delivery of therapeutic agents.

5

Detailed Description of Preferred Embodiments

The invention will now be described in greater detail, by way of illustration only, with reference to the following Examples.

10

Example 1

Synthesis of NHS-activated PVP-co-PAA

(a) Polymerisation of acrylic acid and N-vinyl-2-pyrrolidone

15

The polymer is formed via the polymerisation of monomers such as N-vinyl-2-pyrrolidone and acrylic acid, as shown in Figure 3.

20

A number of methods may be used to initiate the polymerisation, such as free radical, ionic (cationic or anionic), thermal, UV, redox etc. Free radical polymerisation is the preferred polymerisation method and 2-2'-azo-bis-isobutyronitrile (AIBN) is the preferred initiator. The AIBN decomposes into two radicals which can then attack the carbon-carbon double bond in the vinylic monomer (acrylic acid) as shown in Figure 4.

25

This will continue until termination of chain growth, via combination, disproportionation etc.

30

The reaction solvent may be N,N'-dimethylformamide, toluene, or any other suitable solvent with a boiling point greater than 100°C. Toluene is the currently preferred solvent.

A typical polymerisation method is as follows:

Solvent is charged to the reaction flask. Usually, around 5-10ml of solvent per gram of monomer is sufficient. The flask is heated in an oil bath to a
5 temperature sufficient for the generation of free radicals from the chosen initiator. 80-85°C is the optimum temperature when using AIBN as the initiator. Oxygen-free nitrogen is bubbled through the solvent to remove any dissolved oxygen. Oxygen is also removed from the monomers in the same manner. The initiator is added to the solvent and allowed to dissolve. The
10 monomers are added and the vessel closed. A nitrogen inlet and an escape needle may also be used.

The reaction may be allowed to stand for around 3-24 hours. The reaction mixture is cooled and the polymer is isolated from the solvent/polymer solution
15 by precipitation in 5:1 hexane/isopropanol followed by filtration. Successive washes with diethyl ether are required to remove all traces of polymerisation solvent from the polymer. After successive diethyl ether washes, the polymer is dried under reduced pressure to constant weight.

20 Typical reaction conditions are shown in Table I:

Table I

| Solvent (vol) | Monomer (g) | | AIBN (g) | T (°C) | Time (hrs) | Yield | Mw | Mn | Polydispersity Index (Mw/Mn) |
|--------------------|-----------------|-----------------------|------------------|-----------|---------------|-------|-------|-------|------------------------------|
| | acrylic acid | N-vinyl-2-pyrrolidone | | | | | | | |
| Toluene (100ml) | 1.5 (20mol%) | 8.5 (80mol%) | 0.02 (0.125%) | 80 | 3 | - | - | - | - |
| Toluene (100ml) | 0.7 (10mol%) | 9.3 (90mol%) | 0.02 (0.125%) | 80 | 3 | 54% | 80040 | 38800 | 2.0 |
| Toluene (100ml) | 0.7 (10mol%) | 9.3 (90mol%) | 0.04 (0.25%) | 80 | 3 | 58% | 74240 | 38340 | 1.9 |
| DMF (100ml) | 0.7 (10mol%) | 9.3 (90mol%) | 0.02 (0.125%) | 80 | 3 | 62% | 54000 | 25150 | 2.1 |
| Toluene (100ml) | 0.5 (7.5mol%) | 9.5 (92.5mol%) | 0.02 (0.125%) | 80 | 3 | - | - | - | - |
| Toluene (100ml) | 0.35 (5mol%) | 9.65 (95mol%) | 0.02 (0.125%) | 80 | 3 | - | - | - | - |

(b) Reaction of PVP-co-PAA and N-hydroxysuccinimide in the presence of dicyclohexylcarbodiimide

5 NHS-activated PVP-co-PAA is formed from the reaction of PVP-co-PAA and N-hydroxysuccinimide in the presence of dicyclohexylcarbodiimide (DCC) (Figure 5).

10g of PVP-co-PAA containing 0.094 moles of acrylic acid repeat units is dissolved in 50 ml of dried N,N'-dimethylformamide by stirring in a dry 100ml round bottomed flask. 0.01 moles of N-hydroxysuccinimide (1.15g) is added to the
10 polymer solution and is allowed to dissolve.

DCC (2.06g) is melted in an oven at 60°C and added to the polymer solution. This is left to stir at room temperature for at least 24 hours. The formation of a white precipitate (dicyclohexylurea) is observed. After 24 hours the precipitate is
15 removed by filtration, and the flask and filter washed with a small amount of dry DMF. The polymer is isolated by precipitation in 5:1 hexane/iso-propanol and filtration. The polymer is further purified by repeated washes with dry diethyl ether. The yield is between 50% and 70%.

20 Example 2

Alternative synthesis of NHS-activated PVP-co-PAA

(a) Polymerisation

25 400ml of dried toluene is heated to 80±2°C in a round bottomed flask using an oil bath or isomantle. Oxygen is removed from the solvent by bubbling oxygen-free nitrogen through the toluene for at least 30 minutes. 0.1g (0.006 moles) of azo-iso-butyronitrile (AIBN) dissolved in 2ml of toluene is added to the reaction flask using a syringe, immediately followed by 45.02g (0.406 moles) of 1-vinyl-2-
30 pyrrolidone and 7.02g (0.092 moles) of acrylic acid. The reaction is left under nitrogen at 80±2°C for 17 hours; the polymer is insoluble in toluene and forms a white precipitate as the reaction proceeds. After 17 hours, a further 0.1g (0.006

moles) of AIBN is added and the reaction is kept at $80\pm 2^{\circ}\text{C}$ for one further hour to polymerise any remaining monomer. The polymer is isolated by pouring into 2000 ml of rapidly stirred 1:1 hexane:diethyl ether and subsequent filtration using a 10-16 μm filter. The polymer is dissolved in 200ml of N,N-dimethylformamide (DMF) and stirred for approximately 60 minutes before being filtered through a 10-16 μm filter. The polymer is precipitated in approximately 2000ml of rapidly stirred 5:1 hexane:iso-propanol and isolated by filtration using a 10-16 μm filter. All traces of DMF and toluene are removed by washing and filtration with 500ml of diethyl ether three times. The polymer is dried for at least 72 hours at 60°C *in vacuo*.

(b) NHS-esterification.

The acid content of the polymer is calculated by titration against 1.0M NaOH.

20g of the polymer are dissolved in 160ml of dry DMF in a 250ml round-bottomed flask using a magnetic stirrer. 4.28g (0.037 moles) of NHS are added and allowed to dissolve. 7.67g (0.037 moles) of dicyclohexyldicarbodiimide are dissolved in 10ml of dry DMF and added to the polymer/NHS solution. The flask is sealed and the reaction stirred for 96 hours at room temperature. A DMF insoluble material, dicyclohexylurea, is formed as a reaction by product and this is apparent as a white precipitate present in the reaction solution. After 96 hours the dicyclohexylurea is removed by filtration using a 10-16 μm filter and the polymer isolated by precipitation using 1275ml of 5:1 hexane:iso-propanol. This is removed by filtration using a 10-16 μm filter. The polymer is purified further by dissolving in 170ml of DMF and precipitation in 1275ml of 5:1 hexane:iso-propanol three further times. After the final precipitation the polymer is washed by stirring rapidly in 170ml of diethyl ether until a fine white powder is obtained. This is dried for at least 72 hours at 60°C *in vacuo*.

Example 3

Blending of NHS-activated PVP-co-PAA with freeze-dried albumin

a) Powders of NHS-activated PVP₈₀-co-PAA₂₀ copolymers (ie copolymers consisting of 80mol% vinyl pyrrolidone-derived units and 20mol% acrylic acid-derived units) have been blended (in ratios of 1:1, 2:1 and 4:1) with freeze-dried porcine albumin (Sigma Aldrich; previously buffered to pH 10.5).

5

b) Powders of NHS-activated PVP₇₀-co-PAA₃₀ copolymers (70mol% vinyl pyrrolidone : 30mol% acrylic acid) have been blended (1:1) with freeze-dried human albumin (Baxter human albumin solution (20%) previously buffered to pH 10.5).

10

c) Powders of NHS-activated PVP₇₀-co-PAA₃₀ copolymers have been blended (2:1) with freeze-dried porcine albumin (previously buffered to pH 10.5).

15 Example 4

Blending of NHS-activated PVP-co-PAA with freeze-dried albumin and application to liver tissue

a) Powders of NHS-activated PVP₈₀-co-PAA₂₀ have been blended (1:1) with
20 freeze-dried porcine albumin (Sigma Aldrich; previously buffered to pH 10.5) and delivered onto moist liver tissue. The powder rehydrated rapidly (< 5 minutes) yielding a gel that offers cohesive strength, in addition to exhibiting strong adhesion to the underlying tissue surface.

25 b) Powders of NHS-activated PVP₇₀-co-PAA₃₀ have been blended (1:1) with freeze-dried human albumin (Baxter human albumin solution (20%) previously buffered to pH 10.5) and delivered onto moist liver tissue. The powder rehydrated rapidly (< 5 minutes) yielding a gel that offers cohesive strength, in addition to exhibiting strong adhesion to the underlying tissue surface.

30

Example 5

Blending of NHS-activated PVP-co-PAA with freeze-dried porcine albumin, forming a compressed disc followed by application to liver tissue

- 5 Powders of NHS-activated PVP₇₀-co-PAA₃₀ copolymers have been blended (2:1) with freeze dried porcine albumin (previously buffered to pH 10.5), followed by compression into a thin (<2mm thick) disc and delivered onto moist liver tissue. The disc adheres immediately to the liver tissue and rehydrates gradually over an hour yielding a gel that offers cohesive strength, in addition to exhibiting strong
10 adhesion to the underlying tissue surface.

Example 6

Blending of excipients with powdered NHS-activated PVP₈₀-co-PAA₂₀ and freeze-dried porcine albumin previously buffered to pH 10.5 (PSA)

15

- Powders of NHS-activated PVP₈₀-co-PAA₂₀ and PSA (1:1) have been blended with excipients such as hydroxypropyl cellulose, poly(vinyl pyrrolidone) and microcrystalline cellulose. The powdered mixture was compressed into a disc with a thickness of less than 2mm. These discs adhered immediately to moist porcine
20 liver tissue and rehydrated upon immersion in aqueous solution. After immersion in aqueous solution for 1 hour, they remained adhered to tissue as a crosslinked gel. Adhesion was obtained with concentrations of NHS-activated PVP₈₀-co-PAA₂₀ and PSA from 11.5% to 50% w/w.

25 Example 7

Schematic representation of a sheet according to the invention

- Figure 6 shows (schematically and not to scale) the structure of a typical sheet prepared in accordance with the invention. The sheet comprises a core in the
30 form of a film 1 of poly(lactide-co-glycolide) (PLG) which has a regular array of apertures 5. Layers 2,3 of a tissue-reactive formulation are pressed onto both sides of the film 1 such that the tissue-reactive formulation penetrates into, and

fills, the apertures. Finally, a non-adhesive layer 4, again of PLG, is applied to one surface of the sheet. The non-adhesive layer 4 is also perforated, the perforations 6 being smaller than the apertures 5 in the core film 1.

- 5 The non-adhesive layer 4 may include a chromophore that gives the non-adhesive surface a discernible colour, thereby identifying that surface (and hence indicating which side of the sheet is to be applied to the tissue). Alternatively, the two sides of the sheet may be distinguishable by virtue of a difference in reflectivity of the two surfaces.

10

Example 8

Preparation of multilayer sheet formulation

- 15 This Example describes the preparation of a multilayer tissue-adhesive sheet having the structure illustrated schematically in Example 6. The sheet comprises a PLG core, to both sides of which a particulate mixture of NHS-activated PVP-co-PAA is applied. A PLG barrier layer is applied to one side of the sheet.

8.1 Preparation of poly (DL-lactide-co-glycolide) core film

20

- The core film was prepared by casting from a 10 % w/w solution of poly(D,L-lactide-co-glycolide) (PLG) in dichloromethane. The core film was produced by spreading the 10 % polymer solution using a 300µm K Bar (R K Print Coat Instruments Ltd, Royston, UK) on silicon paper. A K Bar is a device for accurately
25 producing films of a specific thickness from a specific concentration solution. After drying, the thickness of the core film was 30µm.

8.2 Preparation of PLG barrier film

- 30 The barrier film was produced in an analogous manner to the core film, but using a 24µm K Bar. After drying, the thickness of the barrier film was 3µm.

7.3 Preparation of perforations and cutting out of poly(DL-lactide-co-glycolide) core and barrier films

The next step was to perforate the core and barrier films. This was carried out using a heated perforating device in the form of a press that had been adapted for the purpose. The press was fitted with a heated plate, the underside of which was formed with a regular array of pyramidal projections.

The perforations were created by applying the heated plate with pressure to the film. This softened the polymer film, which redistributed itself around the small pyramids. For perforating the core film, the heated plate was set to 90°C and pressed for 10s. The barrier film was perforated using a temperature of 90°C for 5s at a reduced pressing pressure. The perforation size for the core film was 1.3 mm with centre separations of 2.5 mm and the barrier film perforation size was 0.5 mm with centre separations of 2.5 mm. The perforated films were then cut to size, which in this embodiment was a circle of 39.8mm diameter. Due to redistribution of the film material during perforation, the film thickness increased to 90µm for the core film and 8-10µm for the barrier film.

8.4 Preparation of NHS-activated PVP-co-PAA

NHS-activated PVP-co-PAA was prepared as described in Example 1.

8.5 Preparation of Freeze-Dried Buffered Human Serum Albumin

Freeze-dried buffered human serum albumin (FDBHSA) was prepared by mixing Human Albumin 20% solution with a pH10.5 sodium carbonate/sodium phosphate solution. This solution was lyophilised, leaving powdered human albumin containing sodium carbonate and sodium phosphate evenly distributed throughout.

The pH10.5 sodium carbonate/sodium phosphate solution was prepared by as follows:

31.729g (0.30 moles) of anhydrous sodium carbonate was weighed into a sterile 250ml glass bottle. Approximately 200ml of water for injections was added and the anhydrous sodium carbonate was dissolved by mixing on a roller mixer. Once
5 the sodium carbonate had completely dissolved, the solution was poured into a 1000ml volumetric flask and made up to 1000ml with water for injections.

A sodium phosphate solution was made by dissolving 3.560g (0.03 moles) of sodium phosphate monobasic in approximately 50ml of water for injections in a
10 glass bottle on a roller mixer. This was poured into a 100ml volumetric flask and made up to 100ml using water for injections.

The two solutions were mixed in the ratio 470ml of sodium carbonate solution to 90ml of sodium phosphate solution. The two solutions were thoroughly mixed
15 and the pH checked using a Mettler Toledo pH meter. The pH of the solution should be in the range of pH 10-11. If the pH is too low, sodium carbonate solution is added, and, if it is too high, sodium phosphate solution is added, until the pH is within the desired range.

20 Human Albumin 20% solution was mixed 1:1 v/v with pH10.5 sodium carbonate/sodium phosphate in a glass bottle on a roller mixer for around 30 minutes. When fully mixed, the Human albumin/sodium carbonate/phosphate solution was poured into porcelain dishes and frozen in a freezer at approximately -60°C. When the albumin solutions were completely frozen, they were transferred
25 to the drying chamber of an Edwards Supermodulyo freeze-dryer. The chamber was sealed and the vacuum applied. No heat was applied to the shelves and the albumin was left in the freeze-dryer for at least 72 hours. The vacuum achieved was a minimum 10^{-1} mbar.

30 When dry, the material was removed from the freeze-dryer and ground into a fine powder using a pestle and mortar or electric mill.

8.6 Preparation of mixed NHS-activated PVP-co-PAA / FDBHSA powders

5 The NHS-activated PVP-co-PAA and FDBHSA were ground together in a pestle and mortar until a fine powder was obtained. The ground powder was then mixed on a roller mixer for 30min prior to use to ensure the two components were fully integrated.

8.7 Preparation of multilayer sheet

10

The final product was assembled in a Specac FT-IR 40mm die by compression between two pellets. Pieces of silicon paper were used to prevent the finished product sticking to the pellets.

15 With the first pellet in the die, a silicon paper disc was placed in the cavity and a 150mg portion of the ground powder was sprinkled onto the silicon paper. The powder was carefully manipulated with a spatula or plunger so that the powder evenly covered the entire base of the die. The 39.8mm diameter perforated core film was placed on top of the powder layer and firmly pressed so that so that the
20 film was flat and in contact with the powder layer beneath it so that the powder occupied the perforations of the core film. A second 150mg aliquot of powder was sprinkled onto the perforated PLG core film and again gently levelled.

25 The perforated barrier layer was placed on a second piece of silicon paper and positioned on top of the second powder layer.

A second die pellet was introduced, and the assembled die placed into the press and compressed to a pressure of 2 tonnes for 30s. The final product was then removed from between the pellets. The thickness of the final product was in the
30 range 325-425µm.

The side of the sheet to which the barrier layer is applied had a shiny appearance, and was hence distinguishable from the matt surface of the tissue-reactive side.

Example 9

5 Application of sheet to tissue

The tissue surface is prepared in accordance with conventional surgical technique. The sheet is applied onto (and if necessary) around the tissue surface with moderate pressure to ensure satisfactory contact to the tissue. Following
10 application, the sheet may be hydrated with saline solution.

Example 10

Measurement of Adhesive Strength

15 A Universal testing machine (UTM, Zwick/Roell BZ2,5) was used to test the adhesive strength of test materials to freshly excised liver or lung tissue. Details of the testing procedure are summarised below.

A small section of tissue (4 cm × 4 cm × 1 cm (depth)) was prepared and mounted
20 into a purpose-made holder at the base of the test machine. The surface of the tissue was sprayed with water. The test specimen (with sample holder attached to enable subsequent removal) was placed onto the tissue surface with a moderate force to ensure full contact. The material was left on the tissue for 5 minutes and then wholly submerged in water for a further 5 minutes. Whilst holding the tissue
25 in place using a suitable clamp the folded tip of the sample holder was inserted in the grips of the UTM. The sample was positioned appropriately to ensure that the sample was aligned with the grips. The grip was then moved at 180° from the test sample thereby removing the sample from the tissue. The UTM software (Zwick TestXpert ver 9.0) can be used to calculate the energy of adhesion (mJ) of the test
30 material. Adhesion tests were performed on powder compositions of differing compositions.

Table II shows the data obtained by testing compressed films as a function of composition.

Table II

5

| Test medium Substrate | Tissue reactive material | Crosslinkable material | Ratio of components | Mean energy of adhesion (SD)/ mJ (n=6) |
|--------------------------|---|------------------------|---------------------|--|
| Porcine liver | NHS-activated PVP ₈₀ -co-PAA ₂₀ | Human albumin | 4:1 | 1.3 (0.29) |
| Porcine liver | NHS-activated PVP ₈₀ -co-PAA ₂₀ | Human albumin | 1:4 | 1.0 (0.43) |
| Porcine liver | NHS-activated PVP ₈₀ -co-PAA ₂₀ | Human albumin | 1:1 | 1.0 (0.27) |

The results listed in Table II demonstrate the adhesion performance of the co-powder formulations of NHS-activated PVP₈₀-co-PAA₂₀ and freeze-dried human albumin.

10

In a further study, Table III illustrates the results of adhesion testing of sheet formulations, (13mm diameter circular discs) studied as a function of the number of apertures in a PLG film with active co-powders pressed into either side of the PLG film. The powders utilised were NHS-activated PVP₈₀-co-PAA₂₀ and human albumin in a 4:1 ratio.

15

Table III

| Test medium | No of apertures in 13mm diameter sheet | Mean energy of adhesion (SD)/ mJ (n=6) |
|---------------|--|--|
| Porcine liver | 0 | 0.39 (0.14) |
| Porcine liver | 10 | 0.75 (0.25) |
| Porcine liver | 20 | 1.14 (0.37) |

- 5 The results listed in Table III demonstrate that the energy of adhesion of multi-layered sheets is proportional to the number of apertures in the PLG inner film.

Claims

1. A tissue-adhesive formulation consisting of a naturally occurring or synthetic polymerisable and/or cross-linkable material in particulate form, the polymerisable and/or cross-linkable material being in admixture with particulate material comprising tissue-reactive functional groups.
2. A formulation according to Claim 1, wherein the ratio of polymerisable and/or cross-linkable material to material comprising tissue-reactive functional groups is between 0.1:1 and 10:1.
3. A formulation according to Claim 2, wherein the ratio of polymerisable and/or cross-linkable material to material comprising tissue-reactive functional groups is between 0.2:1 and 1:1.
4. A formulation according to any preceding claim, wherein the tissue-reactive functional groups are selected from the group consisting of imido ester, p-nitrophenyl carbonate, N-hydroxysuccinimide ester, epoxide, isocyanate, acrylate, vinyl sulfone, orthopyridyl-disulfide, maleimide, aldehyde and iodoacetamide.
5. A formulation according to Claim 4, wherein the tissue-reactive functional groups are N-hydroxysuccinimide esters.
6. A formulation according to any preceding claim, wherein the formulation contains one type of material comprising tissue-reactive functional groups.
7. A formulation according to any one of Claims 1 to 5, wherein the formulation contains two types of materials comprising tissue-reactive functional groups.

8. A formulation according to any preceding claim, wherein the material comprising tissue-reactive functional groups is formed by derivatization of a polymer precursor.

5 9. A formulation according to Claim 8, wherein all or substantially all of the available sites in the polymer precursor are derivatised.

10. A formulation according to Claim 8 or Claim 9, wherein the polymer precursor contains carboxylic acid or alcohol functional groups.

10

11. A formulation according to Claim 10, wherein the polymer precursor is selected from the group consisting of sucrose, cellulose and polyvinylalcohol.

12. A formulation according to Claim 10, wherein the polymer precursor is
15 formed by polymerisation of two or more monomers, and at least one of the monomers contains a carboxylic acid group or a group capable of being reacted with another material to form an acid functionality.

13. A formulation according to Claim 12, wherein the monomers are selected
20 from the group consisting of *N*-vinyl-2-pyrrolidone, acrylic acid, vinyl acetate, vinyl acetic acid, mono-2-(methacryloyloxy)ethyl succinate, methacrylic acid, 2-hydroxyethyl methacrylate, 2-hydroxypropyl methacrylate and (polyethylene glycol) methacrylate.

25 14. A formulation according to Claim 12 or Claim 13, wherein polymerisation is initiated by a free radical initiator.

15. A formulation according to Claim 14, wherein the initiator is selected from the group consisting of benzoyl peroxide, 2,2'-azobisisobutyronitrile, lauroyl
30 peroxide and peracetic acid.

16. A formulation according to any one of Claims 12 to 15, wherein the polymer precursor is poly(N-vinyl-2-pyrrolidone-co-acrylic acid) co-polymer.

17. A formulation according to Claim 16, wherein the poly(N-vinyl-2-pyrrolidone-co-acrylic acid) co-polymer has a molar ratio of acrylic acid-derived units less than 0.60, more preferably less than 0.40.

18. A formulation according to Claim 16, wherein the poly(N-vinyl-2-pyrrolidone-co-acrylic acid) co-polymer has a molar ratio of acrylic acid-derived units between 0.025 and 0.25.

19. A formulation according to any one of Claims 7 to 18, wherein the polymer precursor is derivatised with N-hydroxysuccinimide to form the material comprising tissue-reactive functional groups.

20. A formulation according to Claim 19, wherein the material comprising tissue-reactive functional groups is an N-hydroxysuccinimide ester of poly(N-vinyl-2-pyrrolidone-co-acrylic acid) co-polymer.

21. A formulation according to Claim 20, wherein the material comprising tissue-reactive functional groups has a molar ratio of acrylic acid-derived units between 0.05 and 0.50 and vinyl pyrrolidone-derived units between 0.50 and 0.95.

22. A formulation according to any preceding claim, wherein the concentration of material comprising tissue-reactive functional groups in the formulation is between 10 and 50% w/w.

23. A formulation according to any preceding claim, wherein the polymerisable and/or cross-linkable material is selected from the group consisting of polysaccharides, polylactates, polyols and proteins, and derivatives thereof.

24. A formulation according to any one of Claims 1 to 22, wherein the polymerisable and/or cross-linkable material is, or further comprises, a chemically modified polyalkylene glycol containing multiple primary amino or thiol groups.
- 5 25. A formulation according to Claim 23, wherein the polymerisable and/or cross-linkable material is cross-linked.
26. A formulation according to Claim 23 or Claim 25, wherein the polymerisable and/or cross-linkable material is albumin.
- 10 27. A formulation according to Claim 26, wherein the polymerisable and/or cross-linkable material is porcine, bovine or human albumin.
28. A formulation according to any preceding claim, wherein the polymerisable and/or cross-linkable material is buffered to a pH greater than 7.
- 15 29. A formulation according to any preceding claim, further comprising one or more further components selected from structural polymers, surfactants, plasticisers and other excipients.
- 20 30. A formulation according to any preceding claim, wherein the particles that make up the formulation have a median size in the range 5 μ m to 500 μ m, more preferably 5 μ m to 100 μ m.
- 25 31. A sheet having a multilayer structure, said structure consisting of a core of a naturally occurring or synthetic polymeric material, the core being coated on at least one side thereof with a tissue-adhesive formulation according to any preceding claim.
- 30 32. A sheet according to Claim 31, wherein the core comprises a polymeric material selected from the group consisting of polymers or co-polymers based on

α -hydroxy acids such as polylactide, polyglycolide, polycaprolactone and other polylactones such as butyro- and valerolactone.

- 5 33. A sheet according to Claim 31, wherein the core comprises polymeric material selected from the group consisting of alginates, polyhydroxyalkanoates, polyamides, polyethylene, propylene glycol, water-soluble glass fibre, starch, cellulose, collagen, pericardium, albumin, polyester, polyurethane, polyetheretherketone, polypropylene and polytetrafluoroethylene.
- 10 34. A sheet according to any one of Claims 30 to 33, wherein the core is apertured.
- 15 35. A sheet according to Claim 34, wherein the sheet has a regular array of apertures, and the apertures are between 50 μ m and 2mm in diameter and adjacent apertures are formed at a centre-to-centre separation of between 100 μ m and 5mm.
- 20 36. A sheet according to Claim 35, wherein the apertures account for between 5% and 80% of the overall surface area of the core.
37. A sheet according to any one of Claims 30 to 36, wherein the core has a thickness of 0.005 to 5mm.
- 25 38. A sheet according to any one of Claims 30 to 37, wherein the tissue-adhesive formulation is applied to the core by mechanically compressing a blend of material containing tissue-reactive functional groups and polymerisable and/or cross-linkable material, both in particulate form, onto one or both sides of the core.
- 30 39. A sheet according to Claim 38, wherein the core is coated on both sides with the said blend of material.

40. A sheet according to Claim 39, wherein one surface of the sheet is coated with a non-adhesive material.

41. A sheet according to Claim 40, wherein the non-adhesive material is selected from the group consisting of polyethylene glycols, polylactide and poly(lactide-co-glycolide).

42. A sheet according to Claim 41, wherein the non-adhesive coating includes a visibly-absorbing chromophore.

43. A sheet according to Claim 42, wherein the visibly-absorbing chromophore is methylthioninium chloride.

44. A sheet according to any one of Claims 40 to 43, wherein the coating of non-adhesive material is apertured.

45. A biocompatible and hydratable composition suitable for topical application to internal or external surfaces of the body, which composition comprises a polymer containing tissue-reactive functional groups and a polymer containing groups that are not tissue-reactive functional groups but which are capable of forming hydrogen bonds with groups at the surface of a tissue to which the matrix is applied.

46. A composition as claimed in Claim 45, wherein the tissue-reactive functional groups are selected from the group consisting of imido ester, p-nitrophenyl carbonate, N-hydroxysuccinimide ester, epoxide, isocyanate, acrylate, vinyl sulfone, orthopyridyl-disulfide, maleimide, aldehyde and iodoacetamide, and the groups that are capable of forming hydrogen bonds are selected from amide, lactam, carbonyl, carboxyl, hydroxyl and ether groups.

47. A composition as claimed in Claim 45 or Claim 46, wherein the tissue-reactive groups and the groups that are capable of forming hydrogen bonds are present in the same polymer.

5 48. A composition as claimed in Claim 47, wherein the tissue-reactive groups are tissue-reactive ester groups, and the groups that are capable of forming hydrogen bonds are amide or lactam groups.

10 49. A composition as claimed in Claim 48, wherein the polymer is activated PVP-co-PAA.

50. A composition as claimed in Claim 49, wherein the polymer is NHS-activated PVP-co-PAA.

15 51. A composition as claimed in any one of Claims 45 to 50, which has the form of a sheet, patch, film or the like.

20 52. A method for the manufacture of a sheet according any one of Claims 31 to 44, which method comprises forming a core consisting of naturally occurring or synthetic polymeric material, and coating at least one side of said core with a tissue-adhesive formulation comprising a blend of a naturally occurring or synthetic polymerisable and/or cross-linkable material in particulate form and particulate material consisting of tissue-reactive functional groups.

25 53. A method of joining a tissue surface to another tissue, or of sealing a tissue surface, which method comprises applying to the tissue surface a formulation according to any one of Claims 1 to 30, a sheet according to any one of Claims 31 to 44 or a composition according to any one of Claims 45 to 51.

30 54. Use of a formulation according to any one of Claims 1 to 30, a sheet according to any one of Claims 31 to 44 or a composition according to any one of Claims 45 to 51 to enhance wound healing.

55. Use of a formulation according to any one of Claims 1 to 30, a sheet according to any one of Claims 31 to 44 or a composition according to any one of Claims 45 to 51 to promote wound closure.

5

56. Use of a formulation according to any one of Claims 1 to 30, a sheet according to any one of Claims 31 to 44 or a composition according to any one of Claims 45 to 51 to provide reinforcement in hernia repair procedures.

10

57. Use of a formulation according to any one of Claims 1 to 30, a sheet according to any one of Claims 31 to 44 or a composition according to any one of Claims 45 to 51 for sealing of joined tubular structures such as blood vessels.

15

58. Use of a formulation according to any one of Claims 1 to 30, a sheet according to any one of Claims 31 to 44 or a composition according to any one of Claims 45 to 51 in sealing resected tissue surfaces.

20

59. Use of a formulation according to any one of Claims 1 to 30, a sheet according to any one of Claims 31 to 44 or a composition according to any one of Claims 45 to 51 for sealing air leaks in the lung.

25




60. Use of a formulation according to any one of Claims 1 to 30, a sheet according to any one of Claims 31 to 44 or a composition according to any one of Claims 45 to 51 to promote haemostasis.

61. Use of a formulation according to any one of Claims 1 to 30, a sheet according to any one of Claims 31 to 44 or a composition according to any one of Claims 45 to 51 for delivering a drug or other therapeutic agent.

30

62. Use of a formulation according to any one of Claims 1 to 30, a sheet according to any one of Claims 31 to 44 or a composition according to any one of Claims 45 to 51 for preventing post-surgical adhesions.

1/3

Figure 1Figure 2Figure 3

2/3

Figure 4






Figure 5



3/3

Figure 6



BEST AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

ational Application No
/GB2004/001464

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61L15/22 A61L15/32 A61L24/10 A61L24/04 A61L26/00
A61L31/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| X | WO 02/34304 A (TISSUEMED LTD ; VELADA JOSE (GB); BURNETT STUART (GB); EDWARDSON PE) 2 May 2002 (2002-05-02) page 1, line 9 - page 2, line 13 | 1-62 |
| A | DE 198 59 611 A (CENTEON PHARMA GMBH) 29 June 2000 (2000-06-29) page 1, line 20 - line 59 claims 1-4,7,8 ----- -/- | 1-62 |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *Z* document member of the same patent family

Date of the actual completion of the international search

3 September 2004

Date of mailing of the international search report

15/09/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Heck, G

INTERNATIONAL SEARCH REPORT

ational Application No

.../GB2004/001464

| C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT | | |
|--|--|-----------------------|
| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
| A | <p>IWATA H ET AL: "A novel surgical glue composed of gelatin and N-hydroxysuccinimide activated poly(L-glutamic acid): - Part 1. Synthesis of activated poly(L-glutamic acid) and its gelation with gelatin"</p> <p>BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 19, no. 20, October 1998 (1998-10), pages 1869-1876, XP004161460 ISSN: 0142-9612 abstract</p> | 1-62 |
| A | <p>WO 01/56475 A (FORTUNE DAVID ;MANDLEY DAVID (GB); TISSUEMED LTD (GB); VELADA JOSE) 9 August 2001 (2001-08-09) claims; examples</p> | 1-62 |
| A | <p>WO 01/30410 A (TISSUEMED LTD ;VELADA JOSE (GB); EDWARDSON PETER (GB)) 3 May 2001 (2001-05-03) claims; examples</p> | 1-62 |
| A | <p>WO 01/30405 A (FORTUNE DAVID HARRY ;TISSUEMED LTD (GB); VELADA JOSE (GB)) 3 May 2001 (2001-05-03) claims; examples 1-5</p> | 1-62 |
| A | <p>US 5 292 362 A (EATON ALEXANDER M ET AL) 8 March 1994 (1994-03-08) claims; examples</p> | 1-62 |
| A | <p>WO 99/15210 A (HOUZE DAVID ;MANTELLE JUAN (US); KANIOS DAVID (US); NOVEN PHARMA ()) 1 April 1999 (1999-04-01) claims; examples</p> | 1-62 |
| A | <p>WO 01/58452 A (FORTUNE DAVID ;TISSUEMED LTD (GB); STEWART DOUGLAS (GB); TROTTER P) 16 August 2001 (2001-08-16) claims</p> | 1-62 |
| A | <p>US 5 583 114 A (LEWIS TERRY W ET AL) 10 December 1996 (1996-12-10) claims</p> | 1-62 |

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB2004/001464

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: —
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 53-62 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No
.../GB2004/001464

| Patent document cited in search report | | Publication date | Patent family member(s) | Publication date |
|---|---|---------------------|----------------------------|---------------------|
| WO 0234304 | A | 02-05-2002 | AU 9576501 A | 06-05-2002 |
| | | | CA 2422786 A1 | 02-05-2002 |
| | | | EP 1328300 A1 | 23-07-2003 |
| | | | WO 0234304 A1 | 02-05-2002 |
| | | | JP 2004512314 T | 22-04-2004 |
| | | | US 2004049187 A1 | 11-03-2004 |
| | | | AU 1043601 A | 08-05-2001 |
| | | | | |
| DE 19859611 | A | 29-06-2000 | DE 19859611 A1 | 29-06-2000 |
| | | | AT 222781 T | 15-09-2002 |
| | | | AU 754458 B2 | 14-11-2002 |
| | | | AU 5863899 A | 31-07-2000 |
| | | | CA 2363916 A1 | 06-07-2000 |
| | | | DE 59902496 D1 | 02-10-2002 |
| | | | WO 0038752 A1 | 06-07-2000 |
| | | | EP 1140235 A1 | 10-10-2001 |
| | | | ES 2183606 T3 | 16-03-2003 |
| | | | JP 2002533164 T | 08-10-2002 |
| | | | | |
| WO 0156475 | A | 09-08-2001 | AU 3040501 A | 14-08-2001 |
| | | | CA 2397224 A1 | 09-08-2001 |
| | | | EP 1253857 A1 | 06-11-2002 |
| | | | WO 0156475 A1 | 09-08-2001 |
| | | | JP 2003521326 T | 15-07-2003 |
| WO 0130410 | A | 03-05-2001 | AU 1043601 A | 08-05-2001 |
| | | | WO 0130410 A1 | 03-05-2001 |
| WO 0130405 | A | 03-05-2001 | AU 1043901 A | 08-05-2001 |
| | | | WO 0130405 A1 | 03-05-2001 |
| US 5292362 | A | 08-03-1994 | US 5209776 A | 11-05-1993 |
| | | | AT 183656 T | 15-09-1999 |
| | | | AU 8497991 A | 02-03-1992 |
| | | | CA 2087957 A1 | 28-01-1992 |
| | | | DE 69131556 D1 | 30-09-1999 |
| | | | DE 69131556 T2 | 20-07-2000 |
| | | | EP 0542880 A1 | 26-05-1993 |
| | | | ES 2137930 T3 | 01-01-2000 |
| | | | JP 6507376 T | 25-08-1994 |
| | | | WO 9202238 A1 | 20-02-1992 |
| | | | | |
| WO 9915210 | A | 01-04-1999 | AU 750809 B2 | 25-07-2002 |
| | | | AU 9581398 A | 12-04-1999 |
| | | | CA 2304958 A1 | 01-04-1999 |
| | | | EP 1021204 A2 | 26-07-2000 |
| | | | JP 2001517493 T | 09-10-2001 |
| | | | NO 20001567 A | 25-05-2000 |
| | | | NZ 504108 A | 28-06-2002 |
| | | | WO 9915210 A2 | 01-04-1999 |
| | | | US 6562363 B1 | 13-05-2003 |
| | | | TW 541183 B | 11-07-2003 |
| | | | US 2004018241 A1 | 29-01-2004 |
| | | | | |
| | | | | |
| WO 0158452 | A | 16-08-2001 | AU 3199801 A | 20-08-2001 |
| | | | WO 0158452 A1 | 16-08-2001 |
| US 5583114 | A | 10-12-1996 | AU 2870895 A | 22-02-1996 |

INTERNATIONAL SEARCH REPORT

ational Application No
/GB2004/001464

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|----------------------------|---------------------|
| US 5583114 | A | CA 2194681 A1 | 08-02-1996 |
| | | DE 69529075 D1 | 16-01-2003 |
| | | DE 69529075 T2 | 13-11-2003 |
| | | EP 0772464 A1 | 14-05-1997 |
| | | ES 2186723 T3 | 16-05-2003 |
| | | JP 10503102 T | 24-03-1998 |
| | | WO 9603159 A1 | 08-02-1996 |
| | | US RE38158 E1 | 24-06-2003 |